83 Figure 2 One patient showed a decreased vitamin B12 level; 4 patients showed decreased nerve conduction velocity; and 1 patient was diagnosed with neurosarcoidosis during the process. In the end, 117 participants were eligible for inclusion. As expected, the SFNSL was higher in patients with probable SFN compared to patients without SFN (44 vs 25 respectively, p=0.007), see Table 3. Patients with sarcoidosis without SFN were more likely to be male than patients with sarcoidosis and probable SFN (OR=3.6). No further relevant differences could be found between the three groups. SFN symptoms occurred or were diagnosed at a mean of 6.4±5.3 years after the diagnosis of sarcoidosis. Table 3 Demographics in sarcoidosis patients and healthy controls (mean±std) Group n Age (yrs) Sex Males (n (%)) Height BMI Disease duration sarcoidosis (yrs) SFNSL Healthy control 20 48±12 10 (50%) 176±9 23±2 3±4 Sarcoidosis without SFN 49 52±11 36 (73%) 178±9 26±4 8±6 25±17 Sarcoidosis with probable SFN 48 52±9 21 (44%) 176±11 28±6 9±7 44±11 BMI = body mass index; SFN = small fiber neuropathy; SFNSL = small fiber neuropathy screening list; yrs = years Quantitative Sensory Testing PCA analysis of all measurements at the test foot shows that patients with sarcoidosis and probable SFN could not be distinguished from participants without SFN by the TTT measurements (see Figure 2). Figure 2 also visualizes the correlation between the parameters. CDT MLi, TSL and WDT MLi determined 31.7% of the outcome. These vectors were situated close to each other, indicating a positive correlation, and were aligned with the x-axis, which represents principal component 1 (PC 1). The PHS vector diverges by 90֯ from the WDT MLi, which suggests no correlation. Moreover, PHS was 5 87 5
RkJQdWJsaXNoZXIy MjY0ODMw